CASI Pharmaceuticals (CASI) announced that the Safety Monitoring Committee has completed its review of cohort 4 along with its continued assessment of the first three cohorts of the company’s Phase 1 dose-escalating and safety study of CID-103 in adults with chronic immune thrombocytopenia. The SMC has recommended that the trial continue and the dose escalation to cohort 5 may proceed as per the protocol design.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CASI:
- CASI Pharmaceuticals: Strategic Advancements and Leadership Strengthening Drive Buy Rating with $4.00 Price Target
- CASI Pharmaceuticals Strengthens Board with New Appointment
- Casi Pharmaceuticals appoints Barbara Krebs-Pohl to board of directors
- CASI Pharmaceuticals Reports Q2 2025 Results and Strategic Asset Divestiture
- CASI Pharmaceuticals Faces Setback with FOLOTYN® License Expiration in China